BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsPRNewsWire · Aug 24, 2026
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire · Aug 14, 2026
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanPRNewsWire · Jul 28, 2026Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.29 | -$0.35 | Miss |
| May 15, 2026 | -$0.36 | -$0.19 | Beat |
| Mar 31, 2026 | -$0.28 | -$0.19 | Beat |
| Nov 14, 2025 | -$0.35 | -$0.91 | Miss |
| Aug 14, 2025 | -$0.41 | -$0.34 | Beat |
| May 15, 2025 | -$0.97 | -$0.45 | Beat |